The estimated Net Worth of Neil Gregory Almstead is at least $8.54 Million dollars as of 30 January 2024. Neil Almstead owns over 646 units of PTC Therapeutics Inc stock worth over $119,593 and over the last 11 years he sold PTCT stock worth over $5,903,762. In addition, he makes $2,518,770 as Chief Technical Operations Officer at PTC Therapeutics Inc.
Neil has made over 32 trades of the PTC Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 646 units of PTCT stock worth $17,604 on 30 January 2024.
The largest trade he's ever made was exercising 104,038 units of PTC Therapeutics Inc stock on 4 January 2021 worth over $2,156,708. On average, Neil trades about 7,237 units every 88 days since 2014. As of 30 January 2024 he still owns at least 3,706 units of PTC Therapeutics Inc stock.
You can see the complete history of Neil Almstead stock trades at the bottom of the page.
Dr. Neil Almstead Ph.D. serves as Chief Technical Operations Officer of the Company. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders, oncology and inflammatory diseases. Dr. Almstead received a B.S. from Clarkson University and a Ph.D. in Organic Chemistry from the University of Illinois at Urbana-Champaign.
As the Chief Technical Operations Officer of PTC Therapeutics Inc, the total compensation of Neil Almstead at PTC Therapeutics Inc is $2,518,770. There are 1 executives at PTC Therapeutics Inc getting paid more, with Stuart Peltz having the highest compensation of $7,759,440.
Neil Almstead is 53, he's been the Chief Technical Operations Officer of PTC Therapeutics Inc since 2018. There are 15 older and 4 younger executives at PTC Therapeutics Inc. The oldest executive at PTC Therapeutics Inc is Dr. Allan Steven Jacobson, 75, who is the Independent Co-Founder, Chairman of Scientific Advisory Board & Director.
Neil's mailing address filed with the SEC is C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD, NJ, 07080.
Over the last 12 years, insiders at PTC Therapeutics Inc have traded over $50,602,930 worth of PTC Therapeutics Inc stock and bought 3,730,934 units worth $57,374,337 . The most active insiders traders include Suisse/ Credit, Adam Koppel, and Bioventures Cayman Ltd Hbm. On average, PTC Therapeutics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $888,748. The most recent stock trade was executed by Pierre Gravier on 16 July 2024, trading 2,269 units of PTCT stock currently worth $77,191.
ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
PTC Therapeutics Inc executives and other stock owners filed with the SEC include: